Volume 30
Number 1
Mar 2022
Back to issue
Case Reports
C.G.J.B. Hogenkamp, S.K. Veneman, E.M.J.M. Backus, Th.F. Veneman

Diabetic ketoacidosis (DKA) is a severe and potentially lethal complication of diabetes. The use of a relatively new class of antihyperglycaemic drugs, the SGLT2 inhibitors, can cause DKA, albeit with a different presentation compared to the ‘classic’ DKA. Therefore, since it might not be recognised at an early stage, awareness of this specific presentation of DKA as a complication of the use of SGLT2 inhibitors is important. In addition, the risk of dapagliflozin-induced DKA can be reduced by timely precautions, in particular around surgery or during fasting. We describe a case of dapagliflozin-associated DKA, and explain its underlying potential mechanisms.

Back to issue - Download PDF